Reuters logo
BRIEF-Merck KGaA, Darmstadt, Germany licenses four oncology research and development programs from Vertex
January 11, 2017 / 2:38 PM / a year ago

BRIEF-Merck KGaA, Darmstadt, Germany licenses four oncology research and development programs from Vertex

Jan 11 (Reuters) - Merck Kgaa

* Merck KGaA, Darmstadt, Germany, licenses four oncology research and development programs from Vertex and becomes a leader in DNA damage and repair

* Merck KGaA, Darmstadt, Germany says as part of agreement, co will license two clinical-stage programs targeting DNA damage and repair

* Merck KGaA, Darmstadt, Germany says entered into licensing agreement with Vertex Pharmaceuticals Incorporated, Boston, USA

* Merck KGaA, Darmstadt, Germany says Vertex will receive an upfront payment of $230 million, in addition to royalties on future net sales

* Merck KGaA, Darmstadt, Germany says agreement with Vertex is for worldwide development, commercialization of four research and development programs

* Merck KGaA, Darmstadt, Germany says will assume full responsibility for development and commercialization of all programs Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below